We also demonstrated that ROR1-cFab was able to specifically inhibit ovarian cancer cell growth and induce apoptosis in ROR1 expressing cells, suggesting that this antibody could be further investigated as an appropriate and promising therapeutic strategy for ROR1-positive human cancers. Here, CFB is linked to ovarian carcinoma.